UAEM calls for recusal of NIH's Special Advisor for Technology Transfer in Xtandi case

On February 23rd 2002, Universities Allied for Essential Medicines (UAEM), wrote to request that the Department of Health and Human Services (HHS) formally recuse Dr. Mark Rohrbaugh, the National Institutes of Health (NIH) Special Advisor for Technology Transfer, from having any decision-making role in the response to the 2022 petition to march-in and exercise other rights in the patents on the prostate cancer drug Xtandi . UAEM is one of the petitioners.

February 23rd, 2022 - Letter to NIH from UAEM to request the recusal of Dr Mark Rohrbaugh from Xtandi March-in Proceedings 

Read more about UAEM's fight to make Xtandi and other essential medicines like it, developed on the University of California, Los Angeles (UCLA) campus, below and here

(Feb 16, 2022) Op-Ed from UAEM student, Tiffany Cacy in the Daily Bruin: US agencies must ensure equitable access to drugs developed with public funds.

(Feb 15, 2022) UAEM's Executive Director for North America, Merith Basey, in Quartz : Biden's quest to lower drug prices shold start with the prostate cancer medication Xtandi